[{"id":"d0f0b253-86bb-4a2f-9757-8886fccb175d","acronym":"","url":"https://clinicaltrials.gov/study/NCT00784303","created_at":"2021-01-18T02:57:51.789Z","updated_at":"2024-07-02T16:36:45.716Z","phase":"Phase 2","brief_title":"Evaluating the Safety and Efficacy of Oral Lenvatinib in Medullary and Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers, Stratified by Histology","source_id_and_acronym":"NCT00784303","lead_sponsor":"Eisai Inc.","biomarkers":" CEACAM5 • CASP3 • CASP7","pipe":"","alterations":" ","tags":["CEACAM5 • CASP3 • CASP7"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Lenvima (lenvatinib)"],"overall_status":"Completed","enrollment":" Enrollment 117","initiation":"Initiation: 11/06/2008","start_date":" 11/06/2008","primary_txt":" Primary completion: 04/11/2011","primary_completion_date":" 04/11/2011","study_txt":" Completion: 03/29/2019","study_completion_date":" 03/29/2019","last_update_posted":"2020-04-22"}]